Evidence map›Paper›PMID 30325021›Full record

Trial reportInternational journal of cancer2019

Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial.

Rhona A Beynon, Rebecca C Richmond, Diana L Santos Ferreira, Andrew R Ness, Margaret May, George Davey Smith, Emma E Vincent, Charleen Adams, Mika Ala-Korpela, Peter Würtz and 7 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Review
  9. Metabolomic Profiles of Nonobese and Obese Women With Gestational Diabetes.The Journal of clinical endocrinology and metabolism · 2023
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Molecular Targets of Natural Compounds with Anti-Cancer Properties.International journal of molecular sciences · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Rhona A BeynonPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.ORCID 0000-0001-5494-9519
Rebecca C RichmondPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Diana L Santos FerreiraPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Andrew R NessThe National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, Upper Maudlin Street, Bristol, United Kingdom.
Margaret MayPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
George Davey SmithPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Emma E VincentMedical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Charleen AdamsPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Mika Ala-KorpelaPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Peter WürtzResearch Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland.
Sebastian SoidinsaloNightingale Health Ltd., Helsinki, Finland.
Christopher MetcalfePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Jenny L DonovanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Athene J LanePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Richard M MartinPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
ProtecT Study Group
PRACTICAL consortium
Bristol City Council · GBUniversity of Bristol · GBBaker Heart and Diabetes Institute · AUNational Institute for Health Research · GBNightingales Medical Trust · INUniversity of Helsinki · FI

Funding

Cancer Research UK 19169Department of Health HTA 96/20/99Medical Research Council MC_UU_00011/1Medical Research Council MC_UU_00011/5Medical Research Council MC_UU_12013/1Medical Research Council MC_UU_12013/2Medical Research Council MC_UU_12013/5Medical Research Council MC_UU_12013/ 5MC_UU_12013/1Wellcome TrustWellcome Trust WT099874MA
6 · The paper itself

Abstract

Lycopene and green tea consumption have been observationally associated with reduced prostate cancer risk, but the underlying mechanisms have not been fully elucidated. We investigated the effect of factorial randomisation to a 6-month lycopene and green tea dietary advice or supplementation intervention on 159 serum metabolite measures in 128 men with raised PSA levels (but prostate cancer-free), analysed by intention-to-treat. The causal effects of metabolites modified by the intervention on prostate cancer risk were then assessed by Mendelian randomisation, using summary statistics from 44,825 prostate cancer cases and 27,904 controls. The systemic effects of lycopene and green tea supplementation on serum metabolic profile were comparable to the effects of the respective dietary advice interventions (R

Indexed as

LycopeneTeaAgedFeeding BehaviorHumansMagnetic Resonance SpectroscopyMaleMetabolomeMetabolomicsMiddle AgedProstate-Specific AntigenProstatic NeoplasmsPyruvic AcidLycopeneProstate-Specific AntigenPyruvic AcidTeadietary interventiongreen tealycopeneMendelian randomisationprostate cancer

Identifiers

PMID30325021
PMCPMC6491994
OpenAlexW2896581114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.